Clinical trials: Tace
Colorectal Cancer Metastatic
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer
- Trial name
- TACE (NCT01959061)
- Testing
- Raltitrexed, Oxaliplatin, lipiodol
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization…
- Trial name
- NCT06904196
- Testing
- Lenvatinib plus SIRT, Lenvatinib
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Extrahepatic Cholangiocarcinoma
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
This is an open-label, single-arm, multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with TACE in the treatment of extrahepatic cholangiocarcinoma.
- Trial name
- NCT05448183
- Testing
- Toripalimab, Gemcitabine,Oxaliplatin
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC
It is postulated that all arterial tumor feeders supplying a HCC tumor are interconnected with each other through the tumor sinusoid, such that when one of the feeders is catheterized for delivery of a liquid embolic agent, the…
- Trial name
- NCT04641637
- Testing
- TACE
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Hepatocellular
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.
- Trial name
- NCT00576056
- Testing
- Sorafenib, TACE
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma
Adjuvant Radiotherapy Comparing TACE for Curative HCC
Despite advances in our understanding of hepatocellular carcinoma (HCC) and its diagnosis, the prognosis for patients with HCC remains disheartening, due to a high recurrence rate and frequent intrahepatic metastasis.
- Trial name
- ARTC-HCC (NCT02125396)
- Testing
- Transarterial chemoembolization, Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC
This is an observational, multicenter, single arm, prospective study to evaluate safety and tolerability of selective and ultraselective drug eluting beads transcatheter intraarterial chemoembolization (DEB-TACE) with up to 3 ml…
- Trial name
- NCT02670122
- Testing
- DEB-TACE
- Where
- Spain
- Volunteers
- 131 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Child-Pugh Class A, Child-Pugh Class B
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer…
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT02762266
- Testing
- Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent
- Where
- 2 sites in United States, Japan
- Volunteers
- 13 people
- Sponsor
- Stanford University
Unresectable Liver Cancer
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma
This study is a single-center, single-arm, prospective study. It enrolls patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06715072
- Volunteers
- 70 people
- Sponsor
- Yao Xie
Colorectal Cancer Metastatic
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)
- Trial name
- NCT07031570
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and the third most frequent cause of death of cancer.Although with the development of medical science, more and more patients diagnose HCC at early stage, a…
- Trial name
- NCT02061956
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00335829
- Testing
- bevacizumab, chemotherapy, embolization therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05171166
- Testing
- HAIC, TACE, FOLFOX
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University
Hepatocellular Carcinoma
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
Transcatheter arterial chemoembolization (TACE) + sorafenib therapy has been demonstrated to exert a beneficial effective on time-to-tumor-progression (TTP) in patients with unresectable hepatocellular carcinoma (HCC) in some…
- Trial name
- NCT02504983
- Testing
- sorafenib, TACE
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC)
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
This study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital …
- Trial name
- NCT07154082
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Wei Zhang
Liver Neoplasms, Hepatocellular Cancer
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone…
- Trial name
- HepSTAR (NCT02958163)
- Testing
- Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy
- Where
- 5 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hepatocellular Cancer, Hepatocellular Carcinoma
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months.
- Conditions
- Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT03937830
- Testing
- durvalumab, Doxorubicin-Eluting Beads, TACE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Hepatocellular
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver…
- Trial name
- CheckMate 74W (NCT04340193)
- Testing
- nivolumab, ipilimumab, TACE
- Where
- 107 sites in United States, Australia and 17 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.
- Trial name
- NCT04559607
- Testing
- Camrelizumab, TACE, Apatinib
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital